Cancer Research Institute
Clinical Trials
MT-6402-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
To evaluate the safety and tolerability of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD). To evaluate efficacy of MT-6402 in subjects with advanced cancer by using obje ...
NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
The overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.
NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
This is a Phase 2 study of a drug called LOXO-292. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. LOXO-292 is experimental because it has not been proven t ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evalua ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations
You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on you ...
Optune Lua for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used concurrently with pemetrexed and platinum-based chemotherapy
Optune Lua is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (“MPM”) to be used concurrently with pemetrexed and platinum-based chemotherapy. ...
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of TTFields together with standard chemotherapy (gemcitabine and nab-paclitaxel) compared to standard chemotherapy (gemcitabine and nab-paclitaxel) without TTFiel ...
PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance
The purpose of this study is to evaluate if the degree of PD-L1 expression and/or certain subtype(s) of KRAS mutation which may impact outcomes (survivals and/or pattern of metastasis) of lung adenocarcinoma. This may help det ...
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
A medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening the symptoms or the participa ...